BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pradaxa dabigatran etexilate regulatory update

FDA's Cardiovascular and Renal Drugs Advisory Committee voted 9-0 that Boehringer's Pradaxa dabigatran should be approved for the reduction of stroke and non-CNS systemic embolism in patients with non-valvular atrial fibrillation (AF). The committee made its decision based on results from the Phase III RE-LY trial, which showed that each dose of Pradaxa studied (110 and 150 mg twice daily) was non-inferior to open-label, adjusted-dose warfarin on the primary endpoint...

Read the full 326 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >